gdc
Breast CancerFDA Approvals, News & UpdatesNewsworthy

Verzenio Approved as Initial Treatment for Metastatic Breast Cancer

The CDK4/CDK6 inhibitor Verzenio received a new indication, for use alone or in combination with an aromatase inhibitor, as initial therapy in women with HR-positive, HER2-negative advanced or metastatic breast cancer.
May 2018 – Cancer Biomarkers and Molecular Testing

On February 26, 2018, the FDA approved a new indication for Verzenio (abemaciclib; from Eli Lilly), a CDK4/CDK6 inhibitor, for use alone or in combination with an aromatase inhibitor, as initial endocrine-based therapy in postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.

“This approval is an important milestone, as it shows that Verzenio plus an aromatase inhibitor substantially reduced tumor size and delayed disease progression in women with hormone receptor-positive, HER-2-negative metastatic breast cancer,” said Joyce O’Shaughnessy, MD, Chair of the Breast Cancer Research Program at Baylor University Medical Center, TX, in a press release. “This information will help inform treatment decisions for each patient, which can be complicated in advanced breast cancer.”

Verzenio was first approved last year for use alone in patients with HR-positive, HER2-negative advanced or metastatic breast cancer progressing after endocrine therapy and chemotherapy, or in combination with Faslodex (fulvestrant) for advanced or metastatic breast cancer progressing after endocrine therapy. In clinical trials, patients who received Verzenio had twice as long a period (28.2 months) without the cancer progressing compared with 14.8 months with placebo.

The most common side effect with Verzenio is diarrhea. Other common side effects are neutropenia, fatigue, infections, nausea, abdominal pain, anemia, vomiting, alopecia, decreased appetite, and leukopenia.

Share this:

Recommended For You
Breast CancerPatient Stories
No Pair, I Don’t Care!
By Kiana Wooten
In May 2019, I went for a routine check-up. As the doctor was doing a normal breast exam, she felt a lump.
Breast CancerSurvivorship
Cancer Took My Breasts and Gave Me Self-Acceptance
By Bethany Sell
As a woman, it was a lot to process when I found out I was losing my breasts to cancer. Besides the shock of having to undergo major surgery, I was overwhelmed by the amount of decision-making ahead.
FDA Approvals, News & UpdatesLymphoma
FDA Approved Breyanzi, Novel Gene Therapy, for Large B-Cell Lymphoma
In February 2021, the FDA approved Breyanzi (lisocabtagene maraleucel; from Juno Therapeutics), a new CAR T-cell therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.
FDA Approvals, News & UpdatesFollicular LymphomaLymphoma
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
In February 2021, the FDA approved Ukoniq (umbralisib; from TG Therapeutics), an oral kinase inhibitor, for the treatment of adults with relapsed or refractory marginal-zone lymphoma (MZL) or with relapsed or refractory follicular lymphoma.
Last modified: July 17, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country